0001723805-18-000001.txt : 20180828 0001723805-18-000001.hdr.sgml : 20180828 20180828165552 ACCESSION NUMBER: 0001723805-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180828 DATE AS OF CHANGE: 20180828 EFFECTIVENESS DATE: 20180828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chase Therapeutics Corp CENTRAL INDEX KEY: 0001723805 IRS NUMBER: 815113723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-320230 FILM NUMBER: 181042195 BUSINESS ADDRESS: STREET 1: 1825 K STREET NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 202-223-7002 MAIL ADDRESS: STREET 1: 1825 K STREET NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 D 1 primary_doc.xml X0708 D LIVE 0001723805 Chase Therapeutics Corp 1825 K STREET NW SUITE 510 WASHINGTON DC DISTRICT OF COLUMBIA 20006 202-223-7002 DELAWARE None None Corporation true 2017 Thomas N. Chase c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 510 Washington DC DISTRICT OF COLUMBIA 20006 Executive Officer Director President and Chief Executive Officer Kathleen Clarence-Smith c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 510 Washington DC DISTRICT OF COLUMBIA 20006 Director Richard P. Dulik c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 510 Washington DC DISTRICT OF COLUMBIA 20006 Executive Officer Secretary John Reher c/o Chase Therapeutics Corporation 1825 K Streeet NW, Suite 510 Washington DC DISTRICT OF COLUMBIA 20006 Director Karoly Nikolich c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 510 Washington DC DISTRICT OF COLUMBIA 20006 Director Pharmaceuticals Decline to Disclose 06b false 2018-08-21 false true false 1 4000000 4000000 0 This filing covers the sale and issuance of Series A-2 Preferred Stock and the underlying Common Stock issuable upon conversion thereof. false 3 0 0 0 false Chase Therapeutics Corp /s/ Thomas N. Chase Thomas N. Chase President and CEO 2018-08-28